Gilead Sciences

GIS.DE

Drug Manufacturers - General · Healthcare

Exchange

Frankfurt Stock Exchange

Winston Score

Winston is curious

Mixed quality — meaningful strengths and weaknesses.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Exceptional

Growth

Mixed

Cash Flow

Mixed

Stability

Good

Valuation

Data not available

Dividends

Good

Track this stock — start free trial

Winston Score History

The full picture

Gilead Sciences is a pharmaceutical company that makes medicines for serious diseases. Its most well-known products treat HIV, hepatitis B, hepatitis C, and cancer. Gilead's HIV drugs — including the Biktarvy and Descovy brands — are among the most widely prescribed in the world, and its antiviral drug Remdesivir was one of the first approved treatments for COVID-19.

Gilead makes money by selling prescription medicines to hospitals, pharmacies, and healthcare providers, primarily in the United States but also across Europe and other global markets. With a gross margin near 80%, the company benefits from strong pricing power on patented drugs, which is a key part of its competitive position. The main risk Gilead faces is patent expiration — when patents run out, cheaper generic versions of its drugs can enter the market and sharply reduce revenue — though its oncology pipeline, built partly through its $21 billion acquisition of Immunomedics, represents a significant growth opportunity.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+10.2% YoY

YoY Growth Rate

Steady revenue growth

EPS Growth

-638.2% YoY

YoY Growth Rate

Earnings declining

Insider Activity

0.2%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

€3.2B cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Growth + cash flow

Gilead Sciences is a rare growth stock that's already generating positive cash flow while growing at 10%. The Winston Score doesn't fully credit this transition from "burner" to "earner."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

79.8%

Premium pricing power — 79.8% gross margin

Profit after running costs

Operating Margin

32.5%

Excellent — 32.5% operating margin

Return on the money invested

ROCE

30.0%

Exceptional — 30.0% return on capital

ROIC above 25%. Every dollar invested in the business earns more than 25 cents back per year.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+5.4%

Slow sales growth (+5.4% YoY)

Profit growth

EPS YoY

-151.4%

Earnings shrinking (-151.4% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

How steady the profit is

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

42.5%

Converts sales into free cash efficiently (42.5%)

Free cash flow margin above 20%. Out of every $100 in sales, more than $20 is real cash they keep.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

2.22

Heavy debt load (2.22)

Covers its interest

Interest Cover

11.45x

Comfortably covers interest (11.4x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend

Dividend Yield

2.32%

no trend

Moderate income — 2.32% yield

Standard yield zone for stable dividend payers. A meaningful piece of total return.

Dividend record

Dividend Growth

+4.0%

no trend

Dividend growing modestly (4.0% YoY)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial